This study extends knowledge of BET inhibitor BI 894999 as a combination drug and identified the p300/CBP inhibitor CCS1477 as a relevant combination partner in NUT carcinoma and supports further exploration in clinical trials. Here, DNER is linked to nut midline carcinoma.